Drugs / CLYM116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07248865 | Dec 2025 → Jul 2026 overdue | — | Climb Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-03 | Climb Bio, Inc. | Results Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy climbbio.com ↗
Our initial data show that this mechanism translated to rapid and durable APRIL suppression and substantial reductions in IgA and Gd-IgA1, with a favorable safety and tolerability profile. |
| 2026-06-05 | Climb Bio, Inc. | Results Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development climbbio.com ↗
Clinical data demonstrated a favorable initial safety profile, supporting continued development of CLYM116 in IgA nephropathy (IgAN). |
| 2025-09-29 | Climb Bio, Inc. | Results Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN climbbio.com ↗
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced results from a completed nonhuman primate (NHP) study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL monoclonal antibody. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLYM116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07248865 ↗ |
| Modality | Monoclonal antibody | “CLYM116 is a humanized monoclonal antibody” NCT07248865 ↗ |
| Route | Subcutaneous | “CLYM116 to be administered by SC injection” NCT07248865 ↗ |